STOKE THERAPEUTICS INC (STOK:NASDAQ)
$29.83 0.47 (1.6008%)
Analysed STOKE THERAPEUTICS INC (STOK:NASDAQ) News Sources
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
06-05-2026
yahoo.com
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
07-05-2026
yahoo.com
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
07-05-2026
yahoo.com
Stoke Therapeutics Q1 Earnings Call Highlights
09-05-2026
marketbeat.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
11-05-2026
yahoo.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18-05-2026
yahoo.com
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
28-05-2026
yahoo.com
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
01-06-2026
yahoo.com
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
04-06-2026
yahoo.com
4 Biotech Stocks Investors Should Watch in 2026
05-06-2026
yahoo.com
What is the current price of STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The current price of STOKE THERAPEUTICS INC (STOK:NASDAQ) is $29.83.
STOKE THERAPEUTICS INC (STOK:NASDAQ) absolute price change since previous trading day?
The absolute price change of STOKE THERAPEUTICS INC (STOK:NASDAQ) since the previous trading day is $0.47.
STOKE THERAPEUTICS INC (STOK:NASDAQ) percentage price change since previous trading day?
The percentage price change of STOKE THERAPEUTICS INC (STOK:NASDAQ) since the previous trading day is 1.6008%.
What is the most recent average sentiment score for STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The most recent average sentiment score for STOKE THERAPEUTICS INC (STOK:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for STOKE THERAPEUTICS INC (STOK:NASDAQ)?
The most recent sentiment for STOKE THERAPEUTICS INC (STOK:NASDAQ) is .
SEC-8K** Filing Available For STOKE THERAPEUTICS INC (STOK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.